White Paper

Navigating The Latest ICH E8(R1) Guideline Revisions: Best Practices For Application With Increased Trial Variabilities

By Sue Batchelor, Director, Clinical Operations and Delivery at Cmed

Clinical Data

Here, we outline the key principles set forth in E8(R1), which was endorsed in May, 2019, and E6(R3), which is scheduled for publication in late 2022, illustrating how Sponsors and Contract Research Organizations (CROs) can achieve compliance.

Cmed has been operating at the highest clinical research standards for over 20 years. Our established change management processes enable us to incorporate industry advances thoroughly and maintaining our trusted provider status. Therefore, we recommend undertaking a holistic review of internal processes to ensure they’re proactive in their intent and capable of accommodating current and future trial variabilities. When selecting their CRO partners, Sponsors should take the time to understand the CRO’s approach to development, planning, and trial conduct. Ideally, the CRO will pursue a cycle of continuous improvement in quality study management that includes proactive and reactive approaches to traceability, accountability, and data integrity.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of ECM Connection? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

Cmed Clinical Research Services